BSXHIGH SIGNALFINANCIAL10-K

BSX delivered exceptional financial performance with net income surging 56% to $2.9B alongside significant debt reduction of 29%, indicating strong operational execution and improved capital structure.

The substantial net income growth exceeding 50% combined with meaningful debt reduction suggests BSX has achieved a strategic inflection point in profitability and financial health. This performance indicates strong underlying business momentum and improved capital allocation efficiency that should support sustained value creation.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

BSX demonstrated exceptional financial performance across all key metrics, with revenue growing 12.5% to $9.1B while net income surged an impressive 56% to $2.9B, indicating significant margin expansion and operational leverage. The company simultaneously strengthened its balance sheet by reducing total debt 29% to $3.8B while increasing current assets 27% and reducing current liabilities 15%, creating substantial financial flexibility. This combination of accelerating profitability, strong cash generation (+32% operating cash flow), and improved capital structure signals a company firing on all cylinders and well-positioned for continued growth.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+56.4%
$1.9B$2.9B

Net income grew 56.4% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+38.8%
$2.6B$3.6B

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+32%
$3.4B$4.5B

Operating cash flow surged 32% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
-29.4%
$5.4B$3.8B

Debt reduced 29.4% — deleveraging strengthens balance sheet and reduces financial risk.

Current Assets
Balance Sheet
+27.1%
$6.9B$8.8B

Current assets grew 27.1% — improving short-term liquidity or inventory/receivables build.

Gross Profit
P&L
+20.6%
$11.5B$13.9B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

SG&A Expense
P&L
+15.1%
$6.0B$6.9B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Current Liabilities
Balance Sheet
-15%
$6.4B$5.4B

Current liabilities reduced — improved short-term financial position and working capital health.

Revenue
P&L
+12.5%
$8.1B$9.1B

Revenue growing 12.5% — solid top-line momentum, watch margins for quality of growth.

Stockholders Equity
Balance Sheet
+11.3%
$21.8B$24.2B

Equity base grew 11.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
These forward-looking statements include, among other things, statements regarding our financial and operating performance; acquisitions; clinical trials; business plans and product performance; new and anticipated product approvals and launches; intellectual property; regulations and accounting pronouncements; legal proceedings; tax matters and regulations; and macroeconomic and geopolitical conditions.
Risk Factors contained in this Annual Report, which we may update in Part II, Item 1A.
Risk Factors in Quarterly Reports on Form 10-Q that we have filed or will file hereafter.
This includes taking actions to drive innovative care, contribute to the communities where we live and work, protect the environment, invest in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly.
Refer to Corporate Responsibility below for additional information regarding measures we are undertaking.
+7 more — sign up free →
REMOVED
This includes taking actions to advance diversity and inclusion, including through financial support of equity initiatives in the communities where we live and work, protecting the environment, investing in our employees' health and well-being, and many other initiatives that we believe ultimately help us create value responsibly.
Refer to discussion of Community Outreach and Corporate Responsibility below for additional information regarding measures we are undertaking.
MedSurg Endoscopy Our Endoscopy business unit develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions with innovative, less-invasive technologies.
Our product offerings include the following: Resolution 360 Clips, Resolution 360 ULTRA Clips and MANTIS Clips, hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures, WallFlex Biliary Stent Systems, used for relieving biliary obstructions by providing bile drainage in both malignant and benign strictures, 3 AXIOS Stents and Electrocautery Enhanced Delivery Systems, the first, and currently only stent systems in the U.S.
indicated for endoscopic drainage of pancreatic pseudocysts and used to facilitate endoscopic drainage of the gallbladder for patients with acute cholecystitis, SpyGlass DS II Direct Visualization Systems and SpyGlass Discover Digital Catheters, the first single-use scopes to enable physicians to take a single-stage approach to diagnostic and therapeutic procedures in the pancreaticobiliary system, including treating patients with bile duct stones, EXALT Model D Single-Use Duodenoscopes for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures, the first U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →